Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Metagenomi Inc.

At Metagenomi, we are accelerating innovation in cell and gene therapy with a wave of proprietary CRISPR-based systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful therapeutic tools that can be leveraged by partners and fuel our own pipeline of potentially curative medicines. Our goal is to revolutionize gene editing and unlock its power for the benefit of patients around the world. *


Period Start 2018-01-01 established (s-off)
  Predecessor University of California, Berkeley
Products Industry CRISPR gene editing technology
  Industry 2 genomics
Persons Person Thomas, Brian C. (Metagenomi 202011 CEO + Co-Founder)
  Person 2 Knowles, Jak (Affini-T Therapeutics 202203 CEO + Co-Founder before Metagenomi 202011– CBO before Leaps by Bayer)
Region Region Emeryville, CA
  Country United States (USA)
  Street 5980 Horton Street
Suite 600
  City 94608 Emeryville, CA
    Address record changed: 2024-01-05
Basic data Employees n. a.
    * Document for »About Section«: Bayer AG. (11/12/20). "Press Release: Metagenomi Closes USD 65 Million Series A Financing Led by Leaps by Bayer and Humboldt Fund". Emeryville, CA & Leverkusen.
Record changed: 2023-07-10


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Metagenomi Inc.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News Bayer Aignostics Collaboration 650x300px

» top